The platform presentation, “Germline Genetic Testing in Unselected Pancreatic Ductal Adenocarcinoma (PDAC) Patients,” reports findings from Ambry’s collaborative study with University of Pittsburgh, Beth Israel Deaconess Medical Center and HonorHealth/TGen. Read more . . .
Ambry Genetics (Ambry), a leading clinical genetics testing lab, is showcasing groundbreaking research in a platform and a poster presentation at the 2017 American Society of Clinical Oncologists (ASCO) Annual Meeting. These presentations will shed light on hereditary pancreatic, thyroid and breast and colon cancers and demonstrate that a larger segment of the population may benefit from genetic testing than is reported using current genetic testing guidelines.